Patents by Inventor Ulrike Obst
Ulrike Obst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059692Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as described herein. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: November 29, 2021Publication date: February 22, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Ulrike OBST SANDER, Antonio RICCI
-
Publication number: 20240018154Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R4 and A are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: November 29, 2021Publication date: January 18, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Christa Ulrike OBST-SANDER, Antonio RICCI
-
Publication number: 20240002390Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R2?, R3, R4 and R5 are as described herein. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: November 29, 2021Publication date: January 4, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Ulrike OBST SANDER, Antonio RICCI
-
Publication number: 20230054473Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: February 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315591Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315592Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315593Abstract: The application relates to 6 specific heterocyclic compounds, pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220135571Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 21, 2021Publication date: May 5, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Annick Goergler, Georg Jaeschke, Bernd Kuhn, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner, David Hewings, Yvonne Alice Nagel
-
Publication number: 20220112199Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.Type: ApplicationFiled: December 21, 2021Publication date: April 14, 2022Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 11034687Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: GrantFiled: June 17, 2020Date of Patent: June 15, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
-
Publication number: 20210079005Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 10829500Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: GrantFiled: July 31, 2019Date of Patent: November 10, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
-
Publication number: 20200308166Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: ApplicationFiled: June 17, 2020Publication date: October 1, 2020Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
-
Patent number: 10723729Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: GrantFiled: July 16, 2019Date of Patent: July 28, 2020Assignee: Hoffmann-Le Roche Inc.Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
-
Patent number: 10696691Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: GrantFiled: February 13, 2019Date of Patent: June 30, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Walter Vifian, Thomas Woltering
-
Publication number: 20190352312Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: ApplicationFiled: July 31, 2019Publication date: November 21, 2019Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
-
Publication number: 20190337936Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: ApplicationFiled: July 16, 2019Publication date: November 7, 2019Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
-
Patent number: 10414780Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: GrantFiled: July 6, 2018Date of Patent: September 17, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
-
Publication number: 20190270757Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: ApplicationFiled: February 13, 2019Publication date: September 5, 2019Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Walter Vifian, Thomas Woltering
-
Patent number: 10399969Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: GrantFiled: July 12, 2018Date of Patent: September 3, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering